Description de l’essai
A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)
Trial sponsor
NOVARTIS
Médecin ICO - Saint-Herblain
SANDRINE HIRET
Type d'intervention évaluée
Thérapeutique
Date de début de l'essai
23/05/2018
Lien de l'étude : clinicaltrials.gov
